Cycloaddition Strategies for the Synthesis of Diverse Heterocyclic Spirocycles for Fragment-Based Drug Discovery. by King, Thomas et al.





Cycloaddition Strategies for the Synthesis of Diverse 
Heterocyclic Spirocycles for Fragment-Based Drug Discovery 
Thomas A. King, Hannah L. Stewart, Kim T. Mortensen, Andrew J. P. North, Hannah F. Sore and 
David R. Spring* 
Abstract: In recent years the pharmaceutical industry has benefited 
from the advances made in fragment-based drug discovery (FBDD) 
with more than 30 fragment-derived drugs currently marketed or 
progressing through clinical trials. The success of fragment-based 
drug discovery is entirely dependent upon the composition of the 
fragment screening libraries used. Heterocycles are prevalent within 
marketed drugs due to the role they play in providing binding 
interactions; consequently, heterocyclic fragments are important 
components of FBDD libraries. Current screening libraries are 
dominated by flat, sp2-rich compounds, primarily owing to their 
synthetic tractability, despite the superior physicochemical properties 
displayed by more three-dimensional scaffolds. Herein, we report 
step-efficient routes to a number of biologically relevant, fragment-like 
heterocyclic spirocycles. The use of both electron-deficient and 
electron-rich 2-atom donors was explored in complexity-generating 
[3+2]-cycloadditions to furnish products in 3 steps from commercially 
available starting materials. The resulting compounds were primed for 
further fragment elaboration through the inclusion of synthetic handles 
from the outset of the syntheses.  
Introduction 
Heterocycles play a vital role in drug discovery. The 
incorporated heteroatoms provide potential binding interactions 
and the cyclic nature limits structural flexibility, thereby reducing 
the entropic penalty of binding.[1,2] Heterocycles are prevalent in 
marketed drugs both as flat heteroaromatics and as saturated, 
fused or spirocyclic scaffolds. However, this variety is not 
representative of typical screening libraries, which are dominated 
by flat heteroaromatic scaffolds as opposed to more synthetically-
challenging, three-dimensional, saturated, heterocyclic 
scaffolds.[2] 
The failure of high throughput screening (HTS) to provide 
the expected plethora of new drugs with the rise of combinatorial 
chemistry can be strongly attributed to the dominance of sp2-rich, 
flat compounds in HTS libraries.[3–5] This realisation has led to the 
development of new strategies and approaches towards drug 
discovery, including, but by no means limited to, diversity-oriented 
synthesis [6,7] (DOS) and fragment-based drug discovery[8–10] 
(FBDD). FBDD was developed as a means of efficiently sampling 
chemical space by limiting the size (typically <300 kDa) and 
physicochemical properties of screening compounds.[8,10,11] 
Fragment hits, as a result of their small size, typically have weak 
but high-quality binding interactions,[11] with the potential for 
linking, merging and growing into high-affinity drug-like 
candidates without the physical property inflation which is a 
common affliction in the development of candidates identified 
through more traditional methods.[12] As the FBDD field has 
evolved, focus has turned to the importance of the fragment 
library composition. Unfortunately, as with HTS, the robust 
chemistry surrounding aromatic ring systems has led to a 
significant over-representation of flat, sp2-rich scaffolds.[13,14]  
In 2016, a key publication by Astex highlighted that the 
various approaches to drug discovery, for example DOS and 
FBDD, might not be considered orthogonal.[14] In fact, DOS might 
be applied to the construction of more diverse and three-
dimensional fragment screening libraries. DOS is focused on 
using short and divergent synthetic sequences from simple 
starting materials to generate structurally complex and diverse 
scaffolds.[15–22] DOS would provide the ideal strategy to expand 
fragment libraries into three-dimensional chemical space, and this 
challenge has been taken up across industry and academia.[23–29] 
Within three-dimensional fragment space, spirocycles are 
an important class of saturated ring systems.[30,31] The quaternary 
centre provides an inherent three-dimensionality to this sub-set of 
scaffolds whilst their cyclic nature provides all of the benefits of 
reduced flexibility. It has been shown that these properties are 
largely responsible for the biological activity observed with many 
spirocyclic compounds, since they are linked to improved 
physicochemical properties and decreased entropic binding 
penalties.[32,33] 
Figure 1. Examples of spirocycle-containing marketed drugs.[30,31] 
 
Despite almost 47,000 biologically active compounds, 
including a number of marketed drugs (Figure 1), containing a 
spirocyclic scaffold, spirocycles are under-represented in 
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fragment screening libraries.[33] This is likely due to the synthetic 
challenge posed by the generation of the quaternary centre. 
Regio- and stereo-control is difficult to achieve and, historically, 
has required multiple alkylation steps followed by intramolecular 
coupling. Furthermore, these routes have suffered from functional 
group incompatibility which, in turn, has greatly limited the 
incorporation of functional handles for late-stage modification and 
fragment elaboration.[34–36] Moreover, these strategies tend to 
involve long linear sequences, and are therefore of limited use in 
the optimisation of fragment hits.[34–36] 
Despite this, due to their biological potential there has been 
a recent surge of interest in the synthesis of spirocycles for drug 
discovery.[26,30,37–45] In particular, Wang and Bode utilised metal 
hydride hydrogen atom transfer chemistry to generate saturated 
heterocyclic spirocycles in a one-pot reaction from unactivated 
imines (Figure 2a).[46] Work by Griggs et al. also used a one-pot 
reaction, this time to generate highly substituted 2-
spiropiperidines from N-Boc imines, by in-situ Boc-deprotection 
and cyclisation onto a cyclic ketone (Figure 2b).[47] Alternatively, 
the addition of trifluoroborates to oxetanyl N,O-acetals by Carreira 
and co-workers provided compounds for spirocyclisation via 
orthogonal activation of the oxetane and alkyne functionalities 
(Figure 2c).[42] 
Figure 2. Recent advances in the synthesis of heterocyclic spirocycles (a) 
Wang and Bode generated unactivated imines and utilised metal hydride 
hydrogen atom transfer chemistry with manganese to generate a C-centered 
radical, which underwent addition to the unactivated imine to generate the 
spirocycle with an N-centered radical from which the unprotected-N was 
unveiled by a second hydrogen atom transfer: 19 spirocycles with R = alkyl or 
aryl; X = NCbz, S or CH2; n = 5 or 6;[46] (b) Griggs et al. formed highly substituted 
2-spiropiperidines in a one-pot reaction from N-Boc imines via the addition of 
Chan’s diene under Maitland-Japp conditions followed by in-situ Boc-
deprotection and a sodium bicarbonate catalysed cyclisation onto a cyclic 
ketone: 10 spirocycles with R = alkyl or aryl; X = NCbz, O, S or CH2; n = 4, 5 or 
6;[47] (c) Brady and Carreira used the addition of trifluoroborates to oxetanyl N,O-
acetals to generate products with oxetane and alkyne functionalities from which 
spiro heterocycles can be generated by orthogonal activation, such as 
intramolecular opening of the oxetane by the alcohol followed by catalytic 
intramolecular alkyne hydroalkoxylation to close the spirocyclic ring: 5 
spirocycles with R = alkyl, aryl or TMS.[42]  
There is a growing need for the development of step-
efficient and versatile strategies for the synthesis of these 
compounds. Heterocyclic, spirocyclic scaffolds, in particular, 
represent an underexplored and biologically relevant area of 
chemical space. 
Herein, we report the application of DOS-inspired 
methodology to synthesise a diverse range of heterocyclic, 
spirocyclic scaffolds. A key [3+2]-cycloaddition step has been 
utilised to provide high levels of regio-selectivity and improve 
previously lengthy procedures to generate the core quaternary 
carbon centre. Furthermore, synthetic handles for late-stage 
elaboration were incorporated from the outset to aid FBDD hit 
exploration. 
Results and Discussion 
We envisaged that [3+2] cycloadditions could afford a range of 
heterocyclic, spirocyclic scaffolds from simple starting materials in 
just a few steps (Figure 3). Acyclic, electron-rich alkenes could be 
reacted to introduce a heterocyclic moiety which, provided the 
starting material was selected appropriately, could then be formed 
into a spirocycle by the coupling of functional groups on the lower 
half of the molecule (Figure 3a). Alternatively, exo-cyclic, 
electron-deficient alkenes might offer a means to introduce a 
quaternary carbon centre directly (Figure 3b). These later 
compounds could also offer alternative routes to spirocycle 
formation.  
   
Figure 3. The use of both acyclic (a) and exo-cyclic (b) starting materials 
allowed the efficient synthesis of heterocyclic spirocyclic compounds. Based on 
the cyclisation approach taken, different functional handles in the final 
compounds (for example, ester (blue and pink), carbonyl (yellow and green), 
and aromatic (pink and green) moieties) were available for further modifications. 
 





In keeping with the goal of generating diverse scaffolds, we 
aimed to carry out [3+2]-cycloadditions on both acyclic, electron-
rich (1) and exo-cyclic, electron-deficient (5) alkenes. Our initial 
studies focused on the cycloadditions of nitrile-oxide dipole 13 
with both the acyclic alkene and exo-cyclic alkene (Figure 3). 
Spirocycle 3 could be built after the key cycloaddition produced 
isoxazole 2, whereas spirocycle 7 could be formed during the key 
cycloaddition step on a saturated heterocycle (5 or 6).  
Each building block was synthesised in 1-2 step from 
inexpensive, commercially available starting materials (Scheme 1, 
Table 1). Treatment of benzaldehyde (11) with hydroxylamine to 
give the corresponding oxime, followed by addition of N-
chlorosuccinimide, proceeded smoothly to yield chlorooxime 12 
in an excellent 99% yield (Scheme 1a).[48] This was used directly, 
generating 13 in situ, or converted to dipole 13 before addition. 
We imagined that 1,1-disubstituted alkenes such as 1 could 
act as suitable [3+2]-cycloaddition partners. The functional groups 
present provided the synthetic handles necessary for cyclisation 
to form the second ring. As such, following work by Ramesh et al., 
serine ethyl ester 14 was first Boc-protected before an elimination 
reaction using mesyl chloride and triethylamine provided the 
desired 1,1-disubstituted alkene 1 in an excellent yield (Scheme 
1b).[49] The amino acid starting material provided both an amine 
and ester as the synthetic handles required for cyclisation of the 
second ring, with the potential for a range of cyclisation strategies. 
 
 
Scheme 1. Formation of key dipole (a) and acyclic (b) starting materials: (i) 11 
(1.0 equiv.), NH2OH (2.0 equiv.), EtOH, rt, 10min; then NCS (1.1 equiv.), DMF, 
rt, 0.5h, 99%; (ii) 12 (1.0 equiv.), NEt3 (1.0 equiv.), DCE, 0 °C, 3 min, used 
immediately; (iii) 14 (1.0 equiv.), Boc2O (0.95 equiv.), K2CO3 (1.5 equiv.), EtOAc, 
H2O, rt, 12h, 93%; (iv) 15 (1.0 equiv.), MsCl (1.25 equiv.), NEt3 (3.0 equiv.), 
DCM, -15 °C - rt, 2h, 94%. 
The exo-cyclic alkene cycloaddition partners were 
synthesised from a range of commercially available Boc-
protected N-heterocyclic ketones. Heating with Wittig reagent 16 
generated electron-deficient alkenes of general structure 5 in 
good to excellent yields (Table 1). As might be expected, the 
yields obtained closely followed the trend in ring strain; the 4- and 
7-membered cycles reacted with the highest yields, whilst the 
relatively unstrained 6-membered rings proceeded least 
effectively.[50] For symmetrical ketones 4a and 4b the reaction 
proceeded smoothly to yield the 6- and 4-membered heterocycles 
5a and 5b in 94% and 53% respectively. For asymmetrical 
ketones 4c and 4d the reaction led to a separable mixture of 
stereoisomers. The major isomers from these reactions, isolated 
in 41% and 26% yield respectively, were carried forward for the 
subsequent cyclisation. For asymmetrical ketone 4e, the 
increased flexibility afforded by the 7-membered ring reduced the 
chromatographic separation of the two isomers (E:Z) such that 
they were carried forward as a mixture in the ratio 3:2. Critically, 
these intermediates contained both an amine and an ester moiety 




The [3+2]-cycloaddition was initially tested on acyclic, 
electron-rich alkene 1 (Scheme 2). The desired nitrile-oxide dipole 
was generated in situ from previously prepared chlorooxime (12) 
using triethylamine in dichloromethane.[52,53] Pleasingly, this 
provided isoxazole heterocycle 2 in a 58% yield with the regio-
chemistry predicted as proposed by transition state TS-I and 
similar literature strategies.[54–56] The highly reactive ester and 
Boc-protected amine provide the scope for a wide range of ring-
closing strategies. In this case, by way of an example, carbamate 
formation was achieved through ester reduction, using sodium 
borohydride, followed by base-mediated intramolecular ring 
closure. This method furnished spirocycle 3 in moderate yield. 
The crystal structure of spirocycle 3 conclusively confirmed the 
regio-chemical assignment (see SI). 
Table 1. Generation of electron-deficient alkenes for [3+2]-cycloadditions 
 


















Reaction conditions: (i) 4 (1.0 equiv.), 16 (1.1 equiv.), DCM, reflux, 6-44h.[51] 
Notes: [a] Yield corresponding to both isomers combined; [b] Yield 
corresponding to the inseparable mixture of both isomers; [c] 5 equiv. of 16 
used. 





Scheme 2. Synthesis of isoxazole-based spirocycle 3, via [3+2]-cycloaddition 
with nitrile-oxide dipole generated in situ, followed by carbamate formation: (i) 1 
(1.0 equiv.), 12 (6.0 equiv.) NEt3 (6.8 equiv.), DCM, rt, 1h, 58%; (ii) 2 (1.0 equiv.), 
NaBH4 (1.0 equiv.), CH3OH/THF (1:8), 0 °C - rt, 12h, 55%; (iii) 2’ (1.0 equiv.), 
KOtBu (2.0 equiv.), THF, 0 °C, 1h, 56%. 
 
On reviewing the literature, it was hoped that the reaction 
conditions developed for the acyclic alkene could be used on the 
exo-cyclic, electron-deficient alkenes 5a-e.[39,57–61] Unfortunately, 
the reactions of substrates 5a-e failed to proceed under these 
conditions unlike the substitutions performed on the acyclic, di-
substituted alkenes, and alkenes in strained ring systems, 
reported elsewhere. The lack of progress observed at room 
temperature was taken to be a consequence of the higher level of 
steric crowding around the tri-substituted alkene. We therefore 
looked to explore higher temperatures and pressures. Despite 
furnishing the desired spirocycles, this provided its own 
challenges due to the decomposition of the nitrile oxide dipole (13) 
at higher temperatures. Optimisation of these conditions led to the 
realisation that, similar to Zheng et al., pre-forming the nitrile oxide 
dipole (13) using triethylamine at 0 °C was required (Scheme 
1a).[62] The generated dipole was then added to the alkene (5a-e) 
portion-wise over 90 minutes under microwave conditions at 
100 °C. Unfortunately, despite optimising to these conditions, it 
was not possible to push the reaction to completion and, as such, 
the desired spirocycles 7 were all isolated in low to moderate 
yields ranging between 7% and 62% (Table 2).  
In order for these scaffolds to be used in drug discovery, it 
would be necessary to remove all protecting groups. This was 
demonstrated on the 6-membered spirocycle 7a, which 
underwent smooth deprotection using trifluoroacetic acid in 
dichloromethane to provide secondary amine 17a in 68% yield 
(Table 2). 
Having demonstrated the use of the nitrile oxide dipole for 
[3+2]-cycloadditions on both electron-poor and electron-rich 
alkenes we then looked to explore other dipoles. Initially, following 
a published procedure for similar substrates, a benzyl azide [3+2]-
cycloaddition was attempted involving heating the substrates 
under reflux.[63] Again, possibly due to the steric crowding around 
the alkene, only starting material was isolated. It was only by 
heating to 100 °C in a sealed vessel for 48 hours that the desired 
triazole-based spirocycle 8 was isolated in a moderate 34% yield 
(Scheme 3a). Looking beyond [3+2] cycloadditions, hydrazine 
was used in a one-pot cyclisation approach (Scheme 3b). 
 
 
Pleasingly, the Michael-addition and subsequent 
substitution formed hydrazide-based spirocycle 9 in a good 68% 
yield.[64,65] This unusual spirocycle provides multiple handles for 
further elaboration and therefore would be a valuable addition to 
a fragment-screening library. 
Table 2. Synthesis of isoxazole-based spirocycles 7 using freshly-prepared 
nitrile-oxide dipole 
 
Product Reaction Structure Yield (%) 
7a i  50 







7e i  23 
17a ii  68 
Reaction conditions: (i) 5 (1.0 equiv.), 13 (3 x 2.0 equiv.), DCE, 100 °C (MW), 
3 x 30 min; (ii) 7a (1.0 equiv.), TFA (2.0 equiv.), DCM, rt, 22h. 





Scheme 3. Exploring other alkene cycloadditions: (i) 5b (1.0 equiv.), BnN3 (10.0 
equiv.), 100 °C, 48 h, 34%; (ii) 5a (1.0 equiv.), NH2NH2·H2O (1.2 equiv.), EtOH, 
70 °C, 24h, 68%. 
 
Finally, we looked to explore the use of imines in the place 
of electron-poor alkenes in a [2+2]-cycloaddition reaction 
(Scheme 4). This reaction has good precedent on carbocyclic 
systems and therefore it was hoped that it would translate cleanly 
onto a heterocyclic system.[66] The imine (6) was generated from 
the corresponding ketone 4a using para-anisidine in toluene. 
Proving labile under column conditions, 6 was carried through 
without purification into the [2+2]-cycloaddition. The imine was 
trapped with acetoxyacetyl chloride at -78°C to yield the β-lactam 
spirocycle 10 in a moderate 55% yield over the two steps. Again, 
multiple handles for further elaboration make this a versatile 
fragment for FBDD. 
Scheme 4. Exploring imine cyclisations: (i) 4a (1.0 equiv.), p-anisidine (1.0 
equiv.), toluene, reflux, 20h; (ii) 6 (1.0 equiv.), acetoxyacetyl chloride (2.4 equiv.), 
NEt3 (3.0 equiv.), DCM, -78 °C – rt, 20h, 55% over two steps. 
Given that the final compounds will be utilised in their de-
protected forms, conditions were identified to remove all 
protecting groups (Bn, Ac and PMP)[67–69] such that the prophetic 
structures could be utilised for physicochemical property 
calculations. A selection of properties were calculated for these 
final compounds, demonstrating that almost all fragments 
conformed to the so-called “Rule of Three”, which provides an 
important guide to the desirable physicochemical properties of 
fragment screening libraries.[70] Of particular note are the low 
mean value for clogP (0.87) and the high “fraction sp3” (0.54), 
mean number of chiral centres (1.20) and molecular complexity 
(0.77) (Table 3). Additionally, the molecular shape index (0.55) 
demonstrates the increased three-dimensionality of these 
compounds (where a value of 0 represents spherical and a value 




Spirocycle synthesis remains a challenge within organic 
chemistry. Heterocyclic spirocycles, are particularly synthetically 
challenging; however, they represent an under-explored area of 
chemical space with excellent potential within FBDD. Their 
restricted conformation reduces the entropic binding penalty and 
their heterocyclic nature provides opportunities for strong binding 
interactions as well as potential synthetic handles for elaboration. 
Overall, we successfully synthesised nine heterocyclic spirocyclic 
fragments. This collection of scaffolds can be considered 
substantially diverse since they incorporate [4,5], [4,6], [5,5], [5,6] 
and [5,7] spirocycles. Furthermore, the types of heterocycles 
incorporated in the structures varies widely across both rings, 
including isoxazoles, triazoles, cyclic amines, hydrazides and 
carbamates. These rings also provide varied types and positions 
of heteroatoms and thus the potential to identify novel binding 
interactions. Additionally, we have ensured the presence of 
functional handles for further elaboration.  
We have looked to explore the use of cycloadditions as a 
synthetic strategy for heterocyclic spirocycle formation as they 
enable regio-selective and short divergent syntheses. Despite the 
challenges encountered conducting these types of reactions on 
already-sterically-hindered centres, the synthesis of nine diverse, 
novel spirocycles has introduced the powerful potential of this 




Table 3. Mean physicochemical properties 
 
Property[a] Ideal Range[b] This Work 
MW ≤ 300 232.6 
clogP 0 – 2 0.87 
PSA ≤ 60 61.7 
HAC 10 – 16 16.8 
HBA ≤ 3 4.9 
HBD ≤ 3 1.6 
RBC ≤ 3 2.6 
Fsp3 - 0.54 
Molecular Shape Index - 0.55 
Molecular Complexity - 0.77 
[a] MW = molecular weight, PSA = polar surface area, HBA = number of 
hydrogen-bond acceptors, HBD = number of hydrogen-bond donors, HAC = 
heavy atom count, RBC = rotatable bond count; [b] Based on the guidelines 
used by Astex Pharmaceuticals. See the Supporting Information for further 
details. 







All reactions were carried out under nitrogen atmosphere unless 
otherwise stated. Solvents and commercially available reagents were 
dried and purified before use, where appropriate using standard 
procedures. Toluene, hexane, diethyl ether, ethyl acetate (EtOAc), 
petroleum ether (fraction 40-60), methanol, THF, and dichloromethane 
(DCM) were dried and distilled using standard methods from oxygen free 
from solvent dispenser units under an argon atmosphere. Analytical thin 
layer chromatography (TLC) was performed using pre-coated Merck glass 
backed silica gel plates (Silica gel 60 F254). Flash column chromatography 
was undertaken on Fluka or Material Harvest silica gel (230–400 mesh).   
Proton and carbon magnetic resonance spectra were recorded 
using an internal deuterium lock (at 298 K unless stated otherwise) on 
Bruker DPX (400/101 MHz; 1H-13C DUL probe), Bruker Avance III HD 
(400/101 MHz; Smart probe), Bruker Avance III HD (500/126 MHz; Smart 
probe) and Bruker Avance III HD (500/126 MHz; DCH Cryoprobe) 
spectrometers. Chemical shifts (δH) are quoted in ppm to the nearest 
0.01 ppm and are referenced to the residual non-deuterated solvent peak. 
Data are reported as: chemical shift, multiplicity (br = broad; s = singlet; d 
= doublet; t = triplet; q = quartet; qn = quintet; sp = septet; m = multiplet; 
or a combination thereof), coupling constants, number of nuclei, and 
assignment. 
Infrared (IR) spectra were recorded on a Perkin Elmer 1FT-IR 
Spectrometer fitted with an ATR sampling accessory as either solids or 
neat films, either through direct application or deposited in CDCl3. 
Absorption maxima (νmax) are reported in wavenumbers (cm–1) with the 
following abbreviations: w, weak; m, medium; s, strong; br, broad. High-
resolution mass spectra (HRMS) were measured on a Micromass LCT 
Premier spectrometer using electron spray ionization (ESI) techniques. 
Masses are quoted within the 5 ppm error limit. Melting points were 
obtained on a Buchi B-545 melting point apparatus and are uncorrected. 
Chiral products had their optical rotation recorded on an Anton-Paar MCP 
100 polarimeter. [𝛂]𝐃
𝟐𝟎 values are reported in °g–1cm–210–1 at the sodium 
D-line of 598 nm, concentration (c) is given in g(100 mL)–1 in the solvent 
stated.  
N-hydroxybenzimidoyl chloride (12): Benzaldehyde 11 (1.5 g, 14.1 
mmol, 1.0 equiv.) was dissolved in diethyl ether (12 mL) and 
hydroxylamine (50% w/w in H2O, 1.73 mL, 29.3 mmol, 2.0 equiv.) was 
added. The reaction was stirred for 10 minutes, dried (MgSO4), filtered and 
concentrated in vacuo. The residual oil was redissolved in N,N-
dimethylformamide (12 mL), N-chlorosuccinimide (2.1 g, 15.6 mmol, 1.1 
equiv.) was added and the reaction was stirred for 30 minutes. The 
reaction was diluted with water (10 mL) and extracted with ethyl acetate (2 
x 10 mL). The combined organic extracts were washed with water (20 mL) 
and brine (20 mL), dried (Na2SO4), filtered and concentrated in vacuo to 
give the crude product as a yellow oil, which was used directly without 
further purification (2.2 g, 14.0 mmol, 99%); Rf: 0.45 (Pet. Ether 40-
60/EtOAc 4:1); IR (thin film) ν /̃cm–1: 3246 (O-H, m), 3058 (Ar-H, m), 1650 
(C=N, s); 1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 8.94 (br s, 1H), 7.89-
7.86 (m, 2H), 7.47-7.41 (m, 3H); HRMS (ESI) C7H7NOCl m/z: [M+H]+ 
156.0220 (calc. 156.0126). Data agree with that reported in the 
literature.[48] 
 
Ethyl (tert-butoxycarbonyl)-l-serinate (15): L-serine ethyl ester 
hydrochloride 14 (5 g, 29.48 mmol, 1.0 equiv.) and di-tert-butyl dicarbonate 
(6.43 mL, 28.01 mmol, 0.95 equiv.) were dissolved in ethyl acetate (40 mL) 
and water (40 mL). Potassium carbonate (6.11 g, 44.22 mmol, 1.5 equiv.) 
was added to the reaction and it was left to stir overnight at rt. The layers 
were then separated and the aqueous extracted with ethyl acetate (2 × 30 
mL) and the combined organics were washed with brine (50 mL). This was 
then dried over anh. MgSO4. This mixture was filtered and the filtrate was 
concentrated in vacuo to give ethyl (tert-butoxycarbonyl)-l-serinate 15 as 
a pure colourless oil (6.41 g, 27.49 mmol, 93%); Rf: 0.07 (Pet. Ether 40-
60/EtOAc 4:1); IR (thin film) ?̃?/cm–1: 3383 (O-H, br s), 2978 (C-H, w), 1714 
(C=O ester, s), 1692 (C=O carbamide, s), 1158 (C-O, s); 1H NMR (400 
MHz, CDCl3) δ/ppm: 5.44 (br s, 1H), 4.36 (br s, 1H), 4.24 (q, J = 7.0 Hz, 
2H), 3.98–3.89 (m, 2H), 2.30 (br s, 1H), 1.46 (s, 9H), 1.30 (t, J = 7.0 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ/ppm: 170.7, 155.8, 80.3, 63.8, 61.8, 
55.8, 28.3, 14.1; HRMS (ESI) C10H19NO5Na m/z: [M+Na]+ 256.1151 (calc. 
256.1155). [𝛂]𝐃
𝟐𝟎 –17.2 (c = 1.0, CHCl3). Data agree with that reported in 
the literature.[71] 
 
Ethyl 2-((tert-butoxycarbonyl)amino)acrylate (1): Ethyl (tert-
butoxycarbonyl)-l-serinate 15 (6.4 g, 27.44 mmol, 1.0 equiv.) was 
dissolved in dichloromethane (70 mL) at -15 °C. Mesyl chloride (2.65 mL, 
34.30 mmol, 1.25 equiv.) was added dropwise followed by triethylamine 
(11.41 mL, 82.31 mmol, 3.0 equiv.). The reaction was stirred for 30 min 
before being warmed to rt and stirred for a further 2 h. Then one third molar 
HCl (30 mL) was added. The mixture was washed with water and the 
combined organics were dried over anh. MgSO4. This mixture was filtered, 
and the filtrate was concentrated in vacuo to give the crude product. This 
was filtered through Celite with dichloromethane to afford ethyl 2-((tert-
butoxycarbonyl)amino)acrylate 1 as a yellow oil (5.5667 g, 25.86 mmol, 
94%); Rf: 0.60 (Pet. Ether 40-60/EtOAc 4:1); IR (thin film) ?̃?/cm–1: 3420 (N-
H, w), 2980 (C-H, w), 1733 (C=O carbamate, m), 1707 (C=O ester, s), 
1638 (C=C, w), 1152 (C-O, s); 1H NMR (400 MHz, CDCl3) δ/ppm: 7.02 (br 
s, 1H), 6.14 (br s, 1H), 5.72 (d, J = 1.5 Hz, 1H), 4.28 (q, J = 7.0 Hz, 2H), 
1.48 (s, 9H), 1.33 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm: 
164.0, 152.6, 131.5, 104.8, 80.6, 62.0, 28.2, 14.1; HRMS (ESI) 
C10H17NO4Na m/z: [M+Na]+ 238.1046 (calc. 238.1050). Data agree with 
that reported in the literature.[49] 
 
General procedure for synthesis of α,β-unsaturated esters (5): N-Boc 
heterocyclic ketone 4 (1 equiv.) and ethyl (triphenylphosphoranylidine) 
acetate 16 (1.1 equiv.) were dissolved in dichloromethane and refluxed. 
Upon complete conversion of starting material, the mixtures were 
concentrated in vacuo and submitted to flash column chromatography to 
yield the pure products. 
 
tert-Butyl 4-(2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate (5a): 
tert-Butyl 4-oxopiperidine-1-carboxylate 4a (3.50 g, 17.6 mmol, 1.0 equiv.) 
and ethyl (triphenylphosphoranylidene)acetate 16 (6.73 g, 19.3 mmol, 1.1 
equiv.) were dissolved in dichloromethane (50 mL) and refluxed for 17 
hours. The reaction was concentrated in vacuo and submitted to column 
chromatography (Pet. Ether 40-60/EtOAc 9:1 to 4:1) to yield the product, 
tert-butyl 4-(2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate 5a as a 
colourless, crystalline solid (2.53 g, 9.4 mmol, 53%); Rf: 0.24 (Pet. Ether 
40-60/EtOAc 4:1); IR (thin film) ν /̃cm–1: 2972 (C-H, w), 1706 (C=O ester, 
s), 1676 (C=O carbamate, s), 1143 (C-O, s); 1H NMR (400 MHz, CDCl3, 
25°C) δ /ppm: 5.71 (m, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.49 (app. quin, J = 
5.7 Hz, 4H), 2.93 (t, J = 5.5 Hz, 2H), 2.27 (t, J = 5.6 Hz, 2H) 1.47 (s, 9H), 
1.28 (t, J = 7.1, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 166.5, 158.0, 





154.7, 115.4, 80.0, 59.9, 36.6, 29.7, 28.5, 14.4; m.p. 84-86 °C (Lit. Value 
84-86 °C); HRMS (ESI) C14H23NO4Na m/z: [M+Na]+ 292.1515 (calc. 
292.1519). Data agree with that reported in the literature.[72,73] 
 
tert-Butyl 3-(2-ethoxy-2-oxoethylidene) azetidine-1-carboxylate (5b): 
tert-Butyl 3-oxoazetidine-1-carboxylate 4b (2.90 g, 16.9 mmol, 1.0 equiv.) 
and ethyl (triphenylphosphoranylidene)acetate 16 (6.49 g, 18.6 mmol, 1.1 
equiv.) were dissolved in dichloromethane (56 mL) and refluxed for 6 h. 
The reaction was concentrated in vacuo and submitted to column 
chromatography (Pet. Ether 40-60/EtOAc 4:1) to yield the pure product, 
tert-butyl 3-(2-ethoxy-2-oxoethylidene)azetidine-1-carboxylate 5b as a 
colourless oil (3.85 g, 16.0 mmol, 94%);. Rf: 0.29 (Pet. Ether 40-60/EtOAc 
4:1); IR (thin film) ?̃?/cm–1: 2978 (C-H, w), 1725 (C=O carbamate, s), 1704 
(C=O ester, s), 1197 (C-O, s); 1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 
5.76 (quin, J = 2.2 Hz, 1H), 4.81 (m, 2H), 4.58 (m, 2H), 4.17 (q, J = 7.1 Hz, 
2H), 1.45 (s, 9H), 1.27 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
/ppm: 165.2, 156.2, 152.6, 113.7, 80.1, 60.4, 57.8, 28.3, 14.3; HRMS (ESI) 
C12H19NO4Na m/z: [M+Na]+ 264.1215 (calc. 264.1212). Data agree with 
that reported in the literature.[41] 
 
tert-Butyl 3-(2-ethoxy-2-oxoethylidene)pyrrolidine-1-carboxylate 
(5c): tert-Butyl 3-oxopyrrolidine-1-carboxylate 4c (0.50 g, 2.69 mmol, 1.0 
equiv.) and ethyl (triphenylphosphoranylidene)acetate 16 (1.03 g, 2.97 
mmol, 1.1 equiv.) were dissolved in dichloromethane (9 mL) and refluxed 
for 20 h. The reaction was concentrated in vacuo and submitted to column 
chromatography (Pet. Ether 40-60/EtOAc 9:1 to 3:1) to yield the E/Z 
isomers of the product tert-butyl 3-(2-ethoxy-2-oxoethylidene) pyrrolidine-
1-carboxylate 5c as colourless oils. (0.45 g, 1.76 mmol, combined E/Z yield 
65%); Rf: 0.23 (E) and 0.18 (Z) (Pet. Ether 40-60/EtOAc 4:1); (E)-isomer: 
IR (thin film) ν /̃cm–1: 2979 (C-H, w), 1710 (C=O ester, s), 1670 (C=O 
carbamate, s), 1212 (C-O, s), 1165 (C-O, s); 1H NMR (400 MHz, CDCl3, 
25°C) δ /ppm: 5.82 (br s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 4.11 (br s, 2H), 3.56 
(br s, 2H), 3.11 (br s, 2H), 1.46 (s, 9H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR 
(100 MHz, CDCl3) δ /ppm: 166.1, 154.4, 122.4, 112.8, 83.8, 80.0, 77.4, 
60.5, 45.7, 28.6, 14.4; (Z)-isomer: IR (thin film) ν /̃cm–1: 2978 (C-H, w), 
1702 (C=O ester, s), 1676 (C=O carbamate, s), 1215 (C-O, s), 1163 (C-O, 
s); 1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 5.80 (m, 1H), 4.41 (s, 2H), 
4.16 (q, J = 7.1 Hz, 2H), 3.50 (m, 2H), 2.73 (m, 2H), 1.46 (s, 9H), 1.27 (t, 
J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 166.1, 160.6, 154.5, 
113.0, 79.8, 60.2, 50.6, 43.8, 32.9, 28.6, 14.4; HRMS (ESI) C13H21NO4Na 
m/z: [M+Na]+ 278.1356 (calc. 278.1363). Data agreed with that reported in 
the literature.[74] 
 
tert-Butyl 3-(2-ethoxy-2-oxoethylidene) piperidine-1-carboxylate (5d): 
tert-Butyl 3-oxopiperidine-1-carboxylate 4d (4.00 g, 20.1 mmol, 1.0 equiv.) 
and ethyl (triphenylphosphoranylidene)acetate 16 (7.69 g, 22.1 mmol, 1.1 
equiv.) were dissolved in dichloromethane (50 mL) and refluxed for 18 
hours. The reaction was concentrated in vacuo and submitted to column 
chromatography (Pet. Ether 40-60/EtOAc 9:1 to 3:1) to yield the E/Z 
isomers of the product, tert-butyl 3-(2-ethoxy-2-oxoethylidene) piperidine-
1-carboxylate 5d as colourless oils (2.55 g, 9.5 mmol, combined E/Z yield 
47%); Rf: 0.32 (E) and 0.25 (Z) (Pet. Ether 40-60/EtOAc 4:1); (E)-isomer: 
IR (thin film) ν /̃cm–1: 2978 (C-H, w), 1692 (C=O ester, s), 1659 (C=O 
carbamate, s), 1150 (C-O, s); 1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 
5.73 (br s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.92 (br s, 2H), 3.47 (m, 2H), 2.92 
(m, 2H), 1.68 (m, 2H), 1.44 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (100 
MHz, CDCl3) δ /ppm: 166.5, 154.7, 115.7, 80.0, 60.0, 51.4, 44.5, 28.5, 
27.7, 25.4, 14.4; (Z)-isomer: IR (thin film) ν /̃cm–1: 2978 (C-H, w), 1692 
(C=O ester, s), 1662 (C=O carbamate, s), 1212 (C-O, s), 1154 (C-O, s); 
1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 5.65 (br s, 1H), 4.60 (s, 2H), 4.16 
(q, J = 7.1 Hz, 2H), 3.47 (m, 2H), 2.33 (m, 2H), 1.71 (m, 2H), 1.44 (s, 9H), 
1.27 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 165.9, 155.0, 
154.6, 115.5, 79.9, 60.1, 43.4, 34.2, 28.5, 27.6, 25.6, 14.4; HRMS (ESI) 
C14H23NO4Na m/z: [M+Na]+ 292.1521 (calc. 292.1519). Data agree with 
that reported in the literature.[75] 
 
tert-Butyl 3-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate (5e): 
tert-Butyl 3-oxoazepane-1-carboxylate 4e (0.50 g, 2.34 mmol, 1.0 equiv.) 
and ethyl (triphenylphosphoranylidene)acetate 16 (4.08 g, 11.7 mmol, 5.0 
equiv.) were dissolved in toluene (20 mL) and refluxed for 44 hours. The 
reaction was concentrated in vacuo and submitted to column 
chromatography (Pet. Ether 40-60/EtOAc 19:1 to 4:1) to yield an isomeric 
mixture of the products, (E)- and (Z)-tert-Butyl 3-(2-ethoxy-2-
oxoethylidene)azepane1-carboxylate 5e as an orange oil (0.52 g, 1.85 
mmol, 80%); Rf: 0.51 (Pet. Ether 40-60/EtOAc 7:3); IR (thin film) ν /̃cm–1: 
2936 (C-H, w), 1689 (C=O ester, s), 1645 (C=O carbamate, s), 1152 (C-
O, s); 1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 5.73 & 5.70 (s, 1H), 4.16 
& 4.15 (q, J = 7.1 Hz, 2H), 4.12 & 4.04 (s, 2H), 3.29 & 3.20 (m, 2H), 2.79 
& 2.74 (m, 2H), 1.75-1.74 (m, 4H), 1.47 & 1.45 (s, 9H), 1.28 & 1.27 (t, J = 
7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 166.2, 166.1, 161.4, 
160.8, 155.7, 155.1, 116.7, 116.3, 80.0, 79.8, 59.9, 59.8, 55.5, 54.7, 47.4, 
47.2, 30.2, 29.7, 29.0, 28.9, 28.6, 28.5, 27.8, 27.3, 14.4, 14.4; HRMS (ESI) 
C15H25NO4Na m/z: [M+Na]+ 306.1678 (calc. 306.1676). Data agree with 
that reported in the literature.[75] 
 
Ethyl 4-((tert-butoxycarbonyl)amino)-3-phenyl-4,5-dihydroisoxazole-
4-carboxylate (2): Triethylamine (2.2 mL, 15.80 mmol, 6.8 equiv.) was 
added to a mixture of ethyl 2-((tert-butoxycarbonyl)amino)acrylate 1 (500 
mg, 2.32 mmol, 1.0 equiv.) and N-hydroxybenzimidoyl chloride 12 (2.17 g, 
13.94 mmol, 6.0 equiv.) in dichloromethane (40 mL) and the reaction was 
stirred at rt for 1 h. Water (30 mL) was added and the organic layer was 
washed with water (30 mL) and brine (30 mL). The combined organics 
were dried over anh. MgSO4. This mixture was filtered, and the filtrate was 
concentrated in vacuo to give the crude product. This was purified by 
column chromatography (Pet. Ether 40-60/Et2O 4:1) to give ethyl 4-((tert-
butoxycarbonyl)amino)-3-phenyl-4,5-dihydroisoxazole-4-carboxylate 2, as 
off-white amorphous solid (448.6 mg, 1.34 mmol, 58%); Rf: 0.12 (20% 
diethyl ether in pet. ether); IR (thin film) ν /̃cm–1: 3410 (N-H, m), 2976 (C-
H, w), 1741 (C=O, m), 1721 (C=N, s), 1484 (C=C, s), 1308 (N-O, s); 1H 
NMR (400 MHz, CDCl3) δ/ppm: 7.70–7.66 (m, 2H, H11), 7.43–7.38 (m, 3H, 
H12&13), 6.08 (br s, 1H, NH), 4.32 (q, J = 7.0 Hz, 2H), 3.91 (br s, 2H), 1.40 
(s, 9H), 1.32 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ/ppm: 167.6, 
156.3, 153.3, 130.4, 129.8, 128.7, 126.9, 92.4, 81.2, 63.4, 42.7, 28.2, 14.0; 
HRMS (ESI) C17H23N2O5 m/z: [M+H]+ 335.1591 (calc. 335.1607). 
 
tert-Butyl (4-(hydroxymethyl)-3-phenyl-4,5-dihydroisoxazol-4-
yl)carbamate (2’): Ethyl 4-((tert-butoxycarbonyl)amino)-3-phenyl-4,5-
dihydroisoxazole-4-carboxylate 2 (100 mg, 0.30 mmol, 1.0 equiv.), was 
dissolved in an 8:1 THF/methanol mixture (1.8 mL). This was cooled to 
0 °C and sodium borohydride (2.83 mg, 0.07 mmol, 0.25 equiv.) were 
added. The reaction was stirred for 4 h before further sodium borohydride 
(8.49 mmol, 0.21 mmol, 0.75 equiv.) was added. The reaction was stirred 
overnight. It was quenched with sat. aq. NH4Cl (2 mL), and extracted with 
dichloromethane (3 × 5 mL). The combined organics were then dried over 





anh. MgSO4. This mixture was filtered, and the filtrate was concentrated in 
vacuo to give the crude product. This was purified via column 
chromatography (Hexane/EtOAc 1:1) to give tert-butyl (4-(hydroxymethyl)-
3-phenyl-4,5-dihydroisoxazol-4-yl)carbamate 2’ as a white powder (54.0 
mg, 0.18 mmol, 62%); Rf: 0.29 (55% ethyl acetate in hexane); IR (thin film) 
?̃?/cm–1: 3408 (N-H, w), 3278 (O-H, w), 2970 (C-H, w), 1717 (C=O, s), 1545 
(C=C, s); 1H NMR (400 MHz, CDCl3) δ/ppm: 7.66–7.64 (m, 2H), 7.40–7.37 
(m, 3H), 5.74 (br s, 1H), 3.90–3.86 (m, 2H), 3.77–3.73 (m, 1H), 3.30 (d, J 
= 17.5 Hz, 1H), 3.05 (br s, 1H), 1.40 (s, 9H); 13C NMR (101 MHz, CDCl3) 
δ/ppm: 157.3, 154.1, 130.3, 129.6, 128.7, 126.7, 95.4, 80.9, 66.2, 40.4, 
28.2; HRMS (ESI) C15H21N2O4 m/z: [M+H]+ 293.1498 (calc. 293.1501). 
 
3-Phenyl-1,8-dioxa-2,6-diazaspiro[4.4]non-2-en-7-one (3): To a 
solution of potassium tert-butoxide (30.7 mg, 0.27 mmol, 2.0 equiv.) in THF 
(1.4 mL) at 0 °C was added tert-butyl (4-(hydroxymethyl)-3-phenyl-4,5-
dihydroisoxazol-4-yl)carbamate 2’ (40 mg, 0.14 mmol, 1.0 equiv.) and the 
reaction was stirred for 1 h. This was then diluted with sat. aq. NH4Cl (5 
mL) and extracted with dichloromethane (3 × 5 mL). The combined 
organics were dried over anh. MgSO4, filtered and concentrated in vacuo 
to give the crude product. This was purified by column chromatography 
(60% ethyl acetate in hexane) to give 3-phenyl-1,8-dioxa-2,6-
diazaspiro[4.4]non-2-en-7-one 3 as a white powder (17 mg, 0.08 mmol, 
56%); Rf: 0.16 (Hexane/EtOAc 2:3); IR (thin film) ν /̃cm–1: 3226 (N-H, w), 
1765 (C=O, s), 1048 (C-O, s); 1H NMR (400 MHz, CDCl3) δ/ppm: 7.64–
7.62 (m, 2H), 7.48–7.41 (m, 3H), 5.97 (br s, 1H), 4.77 (d, J = 10.0 Hz, 1H), 
4.59 (d, J = 10.0 Hz, 1H), 3.59 (d, J = 18.0 Hz, 1H), 3.49 (d, J = 18.0 Hz, 
1H); 13C NMR (101 MHz, CDCl3) δ/ppm: 156.3, 156.2, 131.1, 129.1, 128.2, 
126.6, 96.1, 73.9, 42.8; HRMS (ESI) C11H10N2O3Na m/z: [M+Na]+ 
241.0576 (calc 241.0584). m.p. 178–179 °C. For crystallographic data, see 
SI. 
 
General method for the cycloaddition of α,β-unsaturated esters with 
N-hydroxybenzimidoyl chloride (7): To a stirred solution of N-
hydroxybenzimidoyl chloride 12 (6 equiv.) in dichloroethane (2 mL) at 0°C 
was added triethylamine (6 equiv.) dropwise. The resulting suspension 
was stirred for 5 minutes and then washed with water (2 x 2 mL), dried 
(MgSO4) and filtered to leave a solution of nitrile oxide intermediate 13 in 
dichloroethane at 0°C. A solution of α,β-unsaturated ester 3 (1 equiv.) was 
prepared in dichloroethane (2 mL). To this solution was added 
approximately 1 equivalent of the nitrile oxide solution and the mixture was 
heated at 100°C (MW) for 30 minutes. Further additions and resubmission 
to heating conditions were performed if the reaction looked incomplete. 
The mixture was then concentrated and submitted to flash column 
chromatography to yield the pure products. 
 
8-(tert-Butyl) 4-ethyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-4,8-
dicarboxylate (7a): Following the general procedure for N-
hydroxybenzimidoyl chloride cycloaddition, tert-butyl 4-(2-ethoxy-2-
oxoethylidene)piperidine-1-carboxylate 5a (50 mg, 0.19 mmol) furnished 
the product, 8-(tert-butyl) 4-ethyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-
ene4,8-dicarboxylate 7a, as a colourless oil after 3 consecutive 
submissions (36 mg, 0.09 mmol, 50%); Rf: 0.18 (Pet. Ether 40-60/EtOAc 
4:1); IR (thin film) ν /̃cm–1: 2978 (C-H, m), 1732 (C=O ester, s), 1687 (C=O 
carbamate/C=N, s), 1139 (C-O, s); 1H NMR (400 MHz, CDCl3, 25°C) δ 
/ppm: 7.61 (m, 2H), 7.39 (m, 3H), 4.17 (q, J = 7.1 Hz, 2H), 4.10 (s, 1H), 
3.95 (m, 2H), 3.28 (m, 2H), 1.98-1.61 (m, 4H), 1.47 (s, 9H), 1.19 (t, J = 7.1 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 167.7, 155.2, 154.7, 130.4, 
129.2, 129.0, 126.5, 87.0, 80.0, 62.3, 62.0, 36.8, 31.2, 28.6, 14.2; HRMS 
(ESI) C21H28N2O5Na m/z: [M+Na]+ 411.1888 (calc. 411.1890). 
 
2-(tert-Butyl) 8-ethyl 7-phenyl-5-oxa-2,6-diazaspiro[3.4]oct-6-ene-2,8-
dicarboxylate (7b): Following the general procedure for N-
hydroxybenzimidoyl chloride cycloaddition, tert-butyl 3-(2-ethoxy-2-
oxoethylidene)azetidine-1-carboxylate 5b (50 mg, 0.21 mmol) furnished 
the product, 2-(tert-butyl) 8-ethyl 7-phenyl-5-oxa-2,6-diazaspiro[3.4]oct-6-
ene2,8-dicarboxylate 7b, as a colourless oil after 3 consecutive 
submissions (5.4 mg, 0.01 mmol, 7%); Rf: 0.31 (Pet. Ether 40-60/EtOAc 
2:1); IR (thin film) ν /̃cm–1: 2978 (C-H, w), 1736 (C=O ester, s), 1698 (C=O 
carbamate/C=N, s), 1392 (N-O, s), 1153 (C-O, s); 1H NMR (400 MHz, 
CDCl3, 25°C) δ /ppm: 7.68 (m, 2H), 7.42 (m, 3H), 4.45 (s, 1H), 4.34 (dd, J 
= 10.8 Hz, 0.8 Hz, 1H), 4.27-4.15 (m, 4H), 4.05 (dd, J = 9.8 Hz, 0.9 Hz, 
1H), 1.46 (s, 9H), 1.20 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 
/ppm: 167.0, 155.9, 154.8, 130.8, 128.9, 128.0, 126.8, 83.4, 80.3, 64.7, 
62.4, 60.5, 57.3, 28.3, 14.0; HRMS (ESI) C19H25N2O5 m/z: [M+H]+ 
361.6087 (calc. 361.6085). 
 
7-(tert-Butyl) 4-ethyl 3-phenyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-
4,7-dicarboxylate (7c): Following the general procedure for N-
hydroxybenzimidoyl chloride cycloaddition, tert-butyl 3-(2-ethoxy-2-
oxoethylidene)pyrrolidine-1-carboxylate 5c (50 mg, 0.20 mmol) furnished 
the product, 7-(tert-butyl) 4-ethyl 3-phenyl-1-oxa-2,7-diazaspiro[4.4]non-2-
ene4,7-dicarboxylate 7c, as a colourless oil after 3 consecutive 
submissions (24 mg, 0.09 mmol, 43%); Rf: 0.24 (Pet. Ether 40-60/EtOAc 
7:3); IR (thin film) ν /̃cm–1: 3375 (Ar-H, w), 2980 (C-H, m), 1728 (C=O ester, 
s), 1704 (C=O carbamate/C=N, s), 1148 (C-O, s); 1H NMR (400 MHz, 
CDCl3, 25°C) δ /ppm: 7.66 (m, 2H), 7.41 (m, 3H), 4.83 (s, 1H), 4.19 (m, 
2H), 3.86 (m, 2H), 2.45 (m, 1H), 2.19 (m, 1H), 1.55 (s, 9H), 1.19 (t, J = 7.5 
Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 169.0, 167.6, 155.3, 150.0, 
130.8, 129.0, 127.1, 90.8, 84.2, 62.4, 57.2, 43.5, 28.6, 28.1, 27.0, 14.2; 
HRMS (ESI) C20H26N2O5Na m/z: [M+Na]+ 397.1738 (calc. 397.1734). 
 
7-(tert-Butyl) 4-ethyl 3-phenyl-1-oxa-2,7-diazaspiro[4.5]dec-2-ene-4,7-
dicarboxylate (7d): Following the general procedure for N-
hydroxybenzimidoyl chloride cycloaddition, tert-butyl 3-(2-ethoxy-2-
oxoethylidene)piperidine-1-carboxylate 5d (50 mg, 0.19 mmol) furnished 
the product, 7-(tert-butyl) 4-ethyl 3-phenyl-1-oxa-2,7-diazaspiro[4.5]dec-2-
ene4,7-dicarboxylate 7d, as a colourless oil after 3 consecutive 
submissions (21 mg, 0.06 mmol, 29%); Rf: 0.29 (Pet. Ether 40-60/EtOAc 
2:1); IR (thin film) ν /̃cm–1: 2975 (C-H, m), 1732 (C=O ester, s), 1687 (C=O 
carbamate/C=N, s), 1150 (C-O, s); 1H NMR (400 MHz, CDCl3, 25°C) δ 
/ppm: 7.64 (m, 2H), 7.40 (m, 3H), 4.17 (q, J = 7.1 Hz, 2H), 4.05 (m, 1H), 
3.59 (m, 2H), 3.32 (m, 2H), 1.99 (m, 2H), 1.83 (m, 1H), 1.66 (m, 1H), 1.45 
(br s, 9H), 1.18 (t, J = 7.12, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 167.8, 
155.4, 154.8, 130.5, 129.1, 129.0, 126.6, 86.9, 80.3, 62.0, 61.2, 58.8, 43.2, 




4,7-dicarboxylate (7e): Following the general procedure for N-
hydroxybenzimidoyl chloride cycloaddition, tert-butyl 3-(2-ethoxy-2-
oxoethylidene)azepane-1-carboxylate 5e (50 mg, 0.18 mmol) furnished 
the product, 7-(tert-butyl) 4-ethyl 3-phenyl-1-oxa-2,7-
diazaspiro[4.6]undec-2-ene-4,7- dicarboxylate 7e, as a colourless oil after 
3 consecutive submissions (17 mg, 0.04 mmol, 23%); Rf: 0.33 (Pet. Ether 





40-60/EtOAc 2:1); IR (thin film) ν /̃cm–1: 2931 (C-H, m), 1722 (C=O ester, 
s), 1682 (C=O carbamate/C=N, s), 1158 (C-O, s); 1H NMR (400 MHz, 
CDCl3, 25°C) δ /ppm: 7.64 (m, 2H), 7.38 (m, 3H), 4.80 & 4.38 (s, ’1H’), 
4.16 (m, 2H), 3.77 (m, 1H), 3.76 & 3.39-3.02 (m, 2H), 1.99 (m, 1H), 1.80 
(m, 3H), 1.62 (m, 2H), 1.49 & 1.31 (s, ’9H’), 1.18 (m, 3H); 13C NMR (100 
MHz, CDCl3) δ /ppm: 168.2, 155.7, 155.5, 130.4, 129.0, 127.0, 126.6, 92.4, 
80.7, 61.9, 59.3, 53.4, 48.7, 34.4, 28.5, 28.3, 22.3, 14.2; HRMS (ESI) 
C22H30N2O5Na m/z: [M+Na]+ 425.2048 (calc. 425.2047). 
 
Ethyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-4-carboxylate 
(17a): To a solution of 8-(tert-butyl) 4-ethyl 3-phenyl-1-oxa-2,8-
diazaspiro[4.5]dec-2-ene-4,8-dicarboxylate 7a (50 mg, 0.13 mmol, 1 
equiv.) in dichloromethane (2 mL) was added trifluoroacetic acid (20 µL, 
0.26 mmol, 2 equiv.) and the solution stirred for 22 hours. The mixture was 
quenched with saturated aqueous sodium bicarbonate (20 mL) and 
extracted with dichloromethane (3 x 7 mL). The combined organic extracts 
were dried (MgSO4), filtered and solvent removed in vacuo. The crude 
mixture was purified by flash column chromatography (Pet. Ether 40-
60/EtOAc 1:0 to 1:1 followed by DCM/MeOH 9:1) to yield the pure product, 
ethyl 3-phenyl-1-oxa-2,8-diazaspiro[4.5]dec-2-ene-4-carboxylate 17a as a 
white amorphous solid (26 mg, 0.09 mmol, 68%); Rf: 0.14 (DCM/MeOH 
9:1); IR (thin film) ν /̃cm–1: 3385 (N-H, w), 2967 (C-H, m), 1732 (C=O ester, 
s), 1671 (C=O carbamate/C=N, s), 1181 (C-O, s); 1H NMR (400 MHz, 
CDCl3, 25°C) δ /ppm: 7.62 (m, 2H), 7.42 (m, 3H), 4.21 (q, J = 7.2 Hz, 2H), 
4.12 (m, 1H), 3.51-3.28 (m, 4H), 2.34-2.08 (m, 4H), 2.04 (s, 1H), 1.24 (t, J 
= 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ /ppm: 167.0, 155.7, 130.9, 
129.1, 128.5, 126.7, 84.0, 62.5, 62.0, 41.0, 40.7, 33.2, 28.1, 14.1; HRMS 
(ESI) C16H21N2O3 m/z: [M+H]+ 289.1533 (calc. 289.1547). 
 
2-(tert-Butyl) 8-ethyl 7-benzyl-2,5,6,7-tetraazaspiro[3.4]oct-5-ene-2,8-
dicarboxylate (8): tert-butyl 3-(2-ethoxy-2-oxoethylidene) azetidine-1-
carboxylate 5b (386 mg, 1.60 mmol, 1.0 equiv.) was dissolved in benzyl 
azide (2 mL, 16.0, 10.0 equiv.) and heated in a sealed tube at 100 °C for 
48 h. This was purified via column chromatography (30% ethyl acetate in 
pet. ether) to give the product, 2-(tert-Butyl) 8-ethyl 7-benzyl-2,5,6,7-
tetraazaspiro[3.4]oct-5-ene-2,8-dicarboxylate 8, as a yellow oil (204 mg, 
0.54 mmol, 34%); Rf: 0.49 (Pet. Ether 40-60/EtOAc 7:3); IR (thin film) 
ν /̃cm–1: 2988 (C-H, w), 1726 (C=O, s), 1631 (C=C, m), 1115 (C-O, s); 1H 
NMR (400 MHz, CDCl3) δ/ppm: 7.30–7.17 (m, 5H), 5.68 (br s, 2H), 4.89 
(br s, 2H), 4.41 (q, J = 7.0 Hz, 2H), 2.65 (br s, 3H), 1.42–1.38 (m, 12H); 
13C NMR (101 MHz, CDCl3) δ/ppm: 154.3, 138.1, 128.9, 128.2, 127.6, 
126.8, 89.5, 79.8, 59.0, 54.8, 51.1, 50.3, 48.4, 28.4, 14.6; HRMS (ESI) 
C19H26N4O4Na m/z: [M+Na]+ 397.1840 (calc. 397.1846). 
 
tert-Butyl 3-oxo-1,2,8-triazaspiro[4.5]decane-8-carboxylate (9): To 
tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate 5a (270 
mg, 1.00 mmol, 1.0 equiv.) in ethanol (0.4 mL) was added hydrazine 
hydrate (58 µL, 1.2 mmol, 1.2 equiv.) and the mixture heated in a sealed 
tube at 70°C for 24 hours. Solvent was removed in vacuo and the mixture 
purified by flash column chromatography (DCM/MeOH 19:1 to 9:1) to yield 
the product, tert-butyl 3-oxo 1,2,8-triazaspiro[4.5]decane-8-carboxylate 9, 
as a colourless oil (173 mg, 0.68 mmol, 68%); Rf: 0.30 (DCM/MeOH 9:1); 
IR (thin film) ν /̃cm–1: 3225 (N-H, m), 2931 (C-H, m), 1668 (C=O carbamate 
and acid hydrazide, br s), 1148 (C-O, s); 1H NMR (400 MHz, CDCl3, 25°C) 
δ /ppm: 7.12 (br s, 1H), 4.03 (br s, 1H), 3.55-3.37 (m, 4H), 2.34 (s, 2H), 
1.79-1.60 (m, 4H), 1.45 (s, 9H); 13C NMR (100 MHz, CDCl3) δ /ppm: 176.8, 
154.6, 79.8, 61.1, 43.0, 40.2, 34.5, 28.4; HRMS (ESI) C12H21N3O3Na m/z: 
[M+Na]+ 278.1479 (calc. 278.1475). 
 
tert-Butyl 4-((4-methoxyphenyl)imino)piperidine-1-carboxylate (6): To 
a solution of tert-butyl 4-oxopiperidine-1-carboxylate 4a (0.50 g, 2.5 mmol, 
1.0 equiv.) in toluene (10 mL) was added para-anisidine (0.31 g, 2.5 mmol, 
1.0 equiv.) and the mixture heated to vigorous reflux in Dean-Stark 
apparatus. After 20 hours, the mixture was cooled and solvent removed in 
vacuo to yield the crude product, which was used directly in the following 
reaction, without purification; Rf: 0.33 (Pet. Ether 40-60/EtOAc 2:3); IR 
(thin film) ν /̃cm–1: 3357 (Ar-H, w), 2976 (C-H, m), 1685 (C=O carbamate 
and imine, s), 1510 (C=C Ar, s), 1234 (C-O, s), 1160 (C-O, s); 1H NMR 
(400 MHz, CDCl3, 25°C) δ /ppm: 6.84 (d, J = 8.8 Hz, 2H), 6.64 (d, J = 8.8 
Hz, 2H), 3.78 (s, 3H), 3.69 (m, 2H), 3.48 (m, 2H), 2.54 (m, 1H), 2.43 (m, 
1H), 2.33 (m, 2H), 1.47 (br s, ’9H’); HRMS (ESI) C17H25N2O3 m/z: [M+H]+ 
305.1874 (calc. 305.1865). 
 
tert-Butyl 3-acetoxy-1-(4-methoxyphenyl)-2-oxo-1,7-
diazaspiro[3.5]nonane-7-carboxylate (10): To a solution of crude 
product, containing tert-butyl 4-((4-methoxyphenyl)imino)piperidine1-
carboxylate 6 (250 mg, 0.82 mmol, 1 equiv.), in dichloromethane (6 mL) at 
-78°C was added triethylamine (0.34 mL, 2.46 mmol, 3 equiv.) dropwise. 
A solution of acetoxyacetyl chloride (0.22 mL, 1.98 mmol, 2.4 equiv.) in 
dichloromethane (2 mL) was added dropwise over 30 minutes and the 
solution was allowed to warm slowly to room temperature and stirred for 
20 hours. The mixture was washed with sodium bicarbonate solution (5%, 
10 mL), HCl (5%, 10 mL) and saturated aqueous sodium chloride (10 mL), 
dried (MgSO4), filtered and the solvent was removed in vacuo. The mixture 
was purified by flash column chromatography (Pet. Ether 40-60/EtOAc 9:1 
to 4:6) to yield the product, tert-butyl 3-acetoxy-1-(4-methoxyphenyl)-2-
oxo-1,7-diazaspiro[3.5]nonane-7-carboxylate 10, as a pale yellow oil (183 
mg, 0.45 mmol, 55%); Rf: 0.48 (Pet. Ether 40-60/EtOAc 4:6); IR (thin film) 
ν /̃cm–1: 3319 (Ar-H, w), 2975 (C-H, m), 1750 (C=O ester and lactam, s), 
1687 (C=O carbamate, s), 1511 (C=C Ar, s), 1215 (C-O, s), 1163 (C-O, s); 
1H NMR (400 MHz, CDCl3, 25°C) δ /ppm: 7.35 (d, J = 9.1 Hz, 2H), 6.87 (d, 
J = 9.1 Hz, 2H), 5.72 (s, 1H), 4.13 (m, 2H), 3.79 (s, 3H), 3.50 (m, 1H), 3.01 
(m, 1H), 2.58 (m, 1H), 2.27 (m, 1H), 2.20 (s, 3H), 2.05 (m, 1H), 1.81 (m, 
1H), 1.65 (m, 1H), 1.46 (s, ’9H’); 13C NMR (100 MHz, CDCl3) δ /ppm: 169.8, 
162.2, 157.6, 154.7, 128.5, 122.3, 114.7, 80.8, 80.3, 79.5, 66.0, 52.1, 55.6, 
33.5, 31.1, 28.5, 20.9; HRMS (ESI) C21H29N2O6 m/z: [M+H]+ 405.2019 
(calc. 405.2026). 
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Heterocyclic spirocycles represent a promising region of chemical space for 
fragment-based drug discovery, combining the advantages of heteroatoms and 
three-dimensionality. The sterically-crowded quaternary carbon has historically 
provided a significant synthetic challenge. This work explores the application of 
cycloaddition reactions as a solution in the synthesis of heterocyclic spirocycles. 
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